Hormonal
Lorcaserin, a selective serotonin 2C receptor agonist, produces modest but clinically significant weight loss (mean 3.2-5.0 kg) compared to placebo, though tolerance may develop over two years of treatment.
Lorcaserin offers a modest weight loss benefit (approx. 3-5 kg) over lifestyle changes alone for obese patients. It works by targeting serotonin receptors to reduce appetite. However, tolerance can develop, leading to weight regain in the second year. It is only prescribed if you lose at least 5% of your body weight in the first 12 weeks; otherwise, it is stopped.
On its own, lorcaserin produces only modest weight loss... with a mean weight loss of 3.2 kg at 1 year... In the BLOOM-DM trial... found a mean weight loss of 5.0 ± 0.35% on lorcaserin 10 mg daily... patients in the BLOOM trial experienced weight regain during the second year of active treatment... suggesting that tolerance to lorcaserin may have developed.
Why this rating
Based on multiple randomized, double-blind, placebo-controlled phase III trials (BLOOM, BLOSSOM, BLOOM-DM).
Source
Pharmacotherapy for obesity: novel agents and paradigms
Sean Manning et al. · Therapeutic Advances in Chronic Disease · 2014
DOI 10.1177/2040622314522848
More from this paper
- The combination of low-dose phentermine and extended-release topiramate produces significantly greater weight loss (up to 10.9%) than monotherapies or placebo, with a favorable benefit-risk profile regarding cardiovascular events despite increased heart rate.Good
- GLP-1 receptor agonists, specifically liraglutide, produce significant weight loss in obese patients with or without type 2 diabetes, representing a repositioning strategy for obesity treatment.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →